Blow To Roche Growth Prospects As TIGIT Lung Cancer Trial Fails

Cancer Combination Fails In Phase III

 
• By Andrew McConaghie

Failure of the tiragolumab plus Tecentriq combination in first line NSCLC patients is a blow to Roche’s immunotherapy aspirations, and its long-term growth strategy.

Roche_Logo_Glass
Tiragolumab had been expected to generate its own peak sales of 2.5bn, and boost those of Tecentriq too. • Source: Alamy

More from Anticancer

More from Therapy Areas